Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved its first two New Drug Applications (NDAs) based on its proprietary OralXR+TM platform technology including the first-ever 24 hour liquid sustained release product.
the details can be read here.
No comments:
Post a Comment